Clinical Trial Results: A Study to Find a Suitable Dose of BI 765883 and to Test Whether it Helps People With Advanced Pancreatic Cancer When Taken Alone or Together With Chemotherapy [Phase 1]

View source ↗

Summary

Phase 1 study evaluating BI 765883 dose in advanced pancreatic cancer, with or without chemotherapy; the trial is terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• BI 765883

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Pancreatic Ductal Adenocarcinoma | Phase 1 | Status: TERMINATED | Results posted: 2026-07-15